10 October 2025 

GenIP Plc

("GenIP" or the "Company")

New Product Launch - Invention Validator

GenIP Plc, a technology consultancy providing Generative Artificial Intelligence (GenAI) services to help research organisations and corporations commercialise their innovations, is pleased to announce the launch of 'Invention Validator', a premium product designed to test user perception and adoption readiness of new technological discoveries. The inaugural project is with a research university in South Africa, focused on evaluating an agricultural biotechnology innovation.

The new service, which is currently being pilot tested, combines GenIP's established Invention Evaluator report with customised market and validation research and has an entry price point in excess of $12,000.

It works in two steps:

1.   a comprehensive evaluation of technical merit, IP strength, and market potential;

2.   a structured collection and assessment of data from target end-users to validate adoption readiness.

GenIP designed a structured questionnaire, which is being distributed to farmers who are the end users and target customers for the new technology. The questionnaire will capture feedback on pricing, adoption barriers, and purchase intent. The responses will be analysed alongside the Invention Evaluator report on the technology. GenIP's Invention Validator will deliver strategic recommendations on commercialization approach, pricing strategy, and partnership priorities to the technology owner.

While the first application targets agriculture, it is anticipated that the methodology can be applied to various sectors, including medical devices, renewable energy systems, advanced materials, environmental monitoring tools, and digital health platforms. Whilst still in pilot launch stage, three universities in the Republic of Chile have already expressed interest in the new product, with one already reviewing a proposal. GenIP plans broader outreach to both corporates and research organisations.

The service is designed as a high-margin, replicable offering, building on GenIP's proprietary technology ranking system already tested and proven from other consulting work. AI-powered automation reduces consulting overheads while maintaining the strategic depth expected by our clients.

Pricing varies by project scope, number of technologies assessed, and validation depth required, with all packages including the foundational Invention Evaluator report.

The launch of 'Invention Validator' is the next step in delivering a suite of new products under GenIP's AI-powered platform, as set out in our recently announced commercial strategy.

Melissa Cruz, CEO of GenIP, commented:

"This new product marks an important milestone in GenIP's evolution from delivering standalone reports to becoming an embedded partner in our clients' commercialization decisions.

Many technologies fail because research teams have to choose between slow, expensive market studies or risky assumptions about user adoption. Invention Validator bridges that gap by delivering fast, actionable insights by pairing AI driven analysis with real user feedback.

Invention Validator is strategically significant because it builds directly on our Invention Evaluator foundation. Organizations start with our core report, then progress naturally to Invention Validator to test real-world adoption. This progression from evaluation to validation and through to execution, creates the opportunity for recurring revenues to drive our growth strategy.

Universities have been asking for this capability and we have demonstrated this demand through its inaugural engagement. As we scale Invention Validator, we are building the high-value, repeatable client journeys that unlock sustained revenue growth."

For further information regarding GenIP, please visit www.genip.ai, or contact:

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

Notes to Editors

About GenIP

GenIP is a next-generation consultancy at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.

Service Offerings

GenIP operates through two synergistic service lines:

Together, these services form a unified GenAI-enabled platform for innovation triage and execution.

Vision & Strategy

GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:

●     Organic Expansion
Scale Invention Evaluator and Recruitment Services through targeted outreach to corporates, VCs, and research institutions, supported by strategic marketing and digital engagement.

●     Service Deepening
Enhance functionality and margin by expanding GenAI capabilities within both service lines-unlocking new use cases and customer segments.

●     Strategic Acquisitions
Pursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.

Forward looking statements

Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.

Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".

For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.

-ENDS-